Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy

Science Translational Medicine

Volumn 2, Issue 55, 2010, Pages

  Atkinson, Rachel L ^a   Zhang, Mei ^a   Diagaradjane, Parmeswaran ^b   Peddibhotla, Sirisha ^a   Contreras, Alejandro ^a   Hilsenbeck, Susan G ^a   Woodward, Wendy A ^b   Krishnan, Sunil ^b   Chang, Jenny C ^a,c   Rosen, Jeffrey M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GOLD NANOPARTICLE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; NANOSHELL; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; GOLD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENICITY; CELL POPULATION; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; HEAT TREATMENT; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CHEMISTRY; HUMAN; HYPERTHERMIC THERAPY; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR RECURRENCE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GOLD; HUMANS; HYPERTHERMIA, INDUCED; MICE; MICE, INBRED BALB C; NANOSHELLS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; RADIATION, IONIZING; TRANSPLANTATION, HETEROLOGOUS;

EID: 78049490200     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001447     Document Type: Article

References (44)

1. Y. Li, J. M. Rosen, Stem/progenitor cells in mouse mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 10, 17-24 (2005).
2. J. M. Rosen, C. T. Jordan, The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673 (2009).
3. M. W. Dewhirst, Z. Vujaskovic, E. Jones, D. Thrall, Re-setting the biologic rationale for thermal therapy. Int. J. Hyperthermia 21, 779-790 (2005).
4. M. R. Horsman, J. Overgaard, Hyperthermia: A potent enhancer of radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 19, 418-426 (2007).
5. J. L. Roti Roti, Cellular responses to hyperthermia (40-46°C): Cell killing and molecular events. Int. J. Hyperthermia 24, 3-15 (2008).
6. E. L. Jones, L. B. Marks, L. R. Prosnitz, Point: Hyperthermia with radiation for chest wall recurrences. J. Natl. Compr. Canc. Netw. 5, 339-344 (2007).
7. M. Franckena, L. C. Lutgens, P. C. Koper, C. E. Kleynen, E. M. van der Steen-Banasik, J. J. Jobsen, J. W. Leer, C. L. Creutzberg, M. F. Dielwart, Y. van Norden, R. A. Canters, G. C. van Rhoon, J. van der Zee, Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: Results in 378 patients. Int. J. Radiat. Oncol. Biol. Phys. 73, 242-250 (2009).
8. P. Gabriele, T. Ferrara, B. Baiotto, E. Garibaldi, P. G. Marini, G. Penduzzu, V. Giovannini, F. Bardati, C. Guiot, Radio hyperthermia for re-treatment of superficial tumours. Int. J. Hyperthermia 25, 189-198 (2009).
9. E. L. Jones, J. R. Oleson, L. R. Prosnitz, T. V. Samulski, Z. Vujaskovic, D. Yu, L. L. Sanders, M. W. Dewhirst, Randomized trial of hyperthermia and radiation for superficial tumors. J. Clin. Oncol. 23, 3079-3085 (2005).
10. C. C. Vernon, J. W. Hand, S. B. Field, D. Machin, J. B. Whaley, J. van der Zee, W. L. van Putten, G. C. van Rhoon, J. D. van Dijk, D. González González, F. F. Liu, P. Goodman, M. Sherar, Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int. J. Radiat. Oncol. Biol. Phys. 35, 731-744 (1996).
11. P. Cherukuri, E. S. Glazer, S. A. Curley, Targeted hyperthermia using metal nanoparticles. Adv. Drug Deliv. Rev. 62, 339-345 (2010).
12. D. P. O'Neal, L. R. Hirsch, N. J. Halas, J. D. Payne, J. L. West, Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 209, 171-176 (2004).
13. R. Weissleder, A clearer vision for in vivo imaging. Nat. Biotechnol. 19, 316-317 (2001).
14. H. Maeda, The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207 (2001).
15. H. Maeda, J. Fang, T. Inutsuka, Y. Kitamoto, Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328 (2003).
16. C. M. Aldaz, Y. Hu, R. Daniel, S. Gaddis, F. Kittrell, D. Medina, Serial analysis of gene expression in normal p53 null mammary epithelium. Oncogene 21, 6366-6376 (2002).
17. M. Zhang, F. Behbod, R. L. Atkinson, M. D. Landis, F. Kittrell, D. Edwards, D. Medina, A. Tsimelzon, S. Hilsenbeck, J. E. Green, A. M. Michalowska, J. M. Rosen, Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 68, 4674-4682 (2008).
18. R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun, S. A. Narod, Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434 (2007).
19. A. A. Onitilo, J. M. Engel, R. T. Greenlee, B. N. Mukesh, Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival.Clin.Med. Res. 7, 4-13 (2009).
20. R. R. Parikh, D. Housman, Q. Yang, D. Toppmeyer, L. D. Wilson, B. G. Haffty, Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, 1056-1063 (2008).
21. C. Ginestier, M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007).
22. D. Chowdhury, X. Xu, X. Zhong, F. Ahmed, J. Zhong, J. Liao, D. M. Dykxhoorn, D. M. Weinstock, G. P. Pfeifer, J. Lieberman, A PP4-phosphatase complex dephosphorylates g-H2AX generated during DNA replication. Mol. Cell 31, 33-46 (2008).
23. C. Lagadec, E. Vlashi, L. Della Donna, Y. Meng, C. Dekmezian, K. Kim, F. Pajonk, Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 12, R13 (2010).
24. X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M. F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, H. Wong, J. Rosen, J. C. Chang, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672-679 (2008).
25. W. A. Woodward, R. G. Bristow, Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin. Radiat. Oncol. 19, 87-95 (2009).
26. P. Diagaradjane, A. Shetty, J. C. Wang, A. M. Elliott, J. Schwartz, S. Shentu, H. C. Park, A. Deorukhkar, R. J. Stafford, S. H. Cho, J. W. Tunnell, J. D. Hazle, S. Krishnan, Modulation of in vivo tumor radiation response via gold nanoshell-mediated vascular-focused hyperthermia: Characterizing an integrated antihypoxic and localized vascular disrupting targeting strategy. Nano Lett. 8, 1492-1500 (2008).
27. E. Charafe-Jauffret, C. Ginestier, F. Iovino, J. Wicinski, N. Cervera, P. Finetti, M. H. Hur, M. E. Diebel, F.Monville, J. Dutcher, M. Brown, P. Viens, L. Xerri, F. Bertucci, G. Stassi, G. Dontu, D. Birnbaum, M. S. Wicha, Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69, 1302-1313 (2009).
28. E. R. Foster, J. A. Downs, Histone H2A phosphorylation in DNA double-strand break repair. FEBS J. 272, 3231-3240 (2005).
29. L. Whitesell, S. L. Lindquist, HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772 (2005).
30. J. L. Roti Roti, Heat-induced alterations of nuclear protein associations and their effects on DNA repair and replication. Int. J. Hyperthermia 23, 3-15 (2007).
31. r 27,000 heat shock protein (hsp27). Cell Growth Differ. 7, 1167-1174 (1996).
32. L. M. Vargas-Roig, M. A. Fanelli, L. A. López, F. E. Gago, O. Tello, J. C. Aznar, D. R. Ciocca, Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect. Prev. 21, 441-451 (1997).
33. S. B. Field, 1985 Douglas Lea memorial lecture. Hyperthermia in the treatment of cancer. Phys. Med. Biol. 32, 789-811 (1987).
34. + breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98, 1777-1785 (2006).
35. W. A.Woodward, M. S. Chen, F. Behbod, M. P. Alfaro, T. A. Buchholz, J. M. Rosen, WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 104, 618-623 (2007).
36. A. Laszlo, I. Fleischer, Heat-induced perturbations of DNA damage signaling pathways are modulated by molecular chaperones. Cancer Res. 69, 2042-2049 (2009).
37. S. K. Calderwood, D. R. Ciocca, Heat shock proteins: Stress proteins with Janus-like properties in cancer. Int. J. Hyperthermia 24, 31-39 (2008).
38. D. Lanneau, A. de Thonel, S. Maurel, C. Didelot, C. Garrido, Apoptosis versus cell differentiation: Role of heat shock proteins HSP90, HSP70 and HSP27. Prion 1, 53-60 (2007).
39. D. R. Ciocca, S. K. Calderwood, Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10, 86-103 (2005).
40. M. Zhang, R. L. Atkinson, J. M. Rosen, Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 107, 3522-3527 (2010).
41. D. Medina, F. S. Kittrell, A. Shepard, L. C. Stephens, C. Jiang, J. Lu, D. C. Allred, M. McCarthy, R. L. Ullrich, Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J. 16, 881-883 (2002).
42. A. L. Welm, S. Kim, B. E. Welm, J. M. Bishop, MET and MYC cooperate in mammary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 102, 4324-4329 (2005).
43. Y. Hu, G. K. Smyth, ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009).
44. Acknowledgments: We thank the Cytometry and Cell Sorting Core Facility at Baylor College of Medicine for flow cytometry assistance, core funding from the NIH (National Center for Research Resources grant S10RR024574, National Institute of Allergy and Infectious Diseases grant AI036211, and National Cancer Institute grant P30CA125123), and also the Baylor Integrated Microscopy Core for help with deconvolution microscopy. We thank Nanospectra Biosciences Inc. for providing the gold nanoshells for these experiments. We thank M. Wicha from the University of Michigan for providing the MC1 xenograft line. We also thank H. LaMarca and S. Greene for constructive criticisms on this manuscript. Funding: These studies were supported by grants from Diana Helis Henry Medical Research Foundation and National Cancer Institute grants R01 CA112305 (J.C.C.), R37 CA16303 (J.M.R.), and P30 CA125123. W.A.W. was supported by NIH grant R01CA138239-01, the State of Texas Grant for Rare and Aggressive Cancers, the University of Texas Health Sciences Center grant KL2RR024149, and the American Airlines Komen Foundation Promise grant KGO81287. Author contributions: R.L.A., W.A.W., S.K., J.C.C., and J.M.R. designed the research; R.L.A., M.Z., and P.D. performed the research; R.L.A., M.Z., S.P., A.C., S.G.H., W.A.W., J.C.C., and J.M.R. analyzed the data; and R.L.A., J.C.C., and J.M.R. wrote the paper. Competing interests: The authors declare that they have no competing interests. Accession numbers: The clinical trial mentioned in the Discussion can be found at ClinicalTrials.gov identifier NCT00848042.